topics generic-drugs 
IIPRD
APRIL 2, 2024
[iv] The outcome of these negotiations therefore can significantly impact the return on investment (ROI) for pharmaceutical companies, potentially influencing their willingness to invest in future drug development. Studies have established a correlation between TRIPS-plus provisions and increased drug prices in importing nations.
SpicyIP
NOVEMBER 21, 2022
We are thrilled to review Prashant Reddy’s new book on the Indian drug regulatory system! Co-authored with Dinesh Thakur their book – The Truth Pill – The Myth of Drug Regulation in India was released this October. Book Review: ‘The Truth Pill: The Myth of Drug Regulation in India’.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
43(B)log
NOVEMBER 13, 2023
Nor did failure to address genericity render the survey inadmissible. of survey respondents selected “Pharmacy operates in full compliance with Section 503A regarding compounded drugs” under the FDCA as an important factor in selecting a compounding pharmacy, in a separate question, 57.4% Although 54.1%
Patently-O
SEPTEMBER 26, 2022
Topics: Enablement / Written Description (All three are biotech / pharma): 3 Cases; Infringement (FDA Labeling): 1 Case; Anticipation (On Sale Bar): 1 Case; Double Patenting (Still the law?) Biogen’s patent claims is directed toward a drug treatment for multiple sclerosis. Those labelled uses are then deleted from the label.
SpicyIP
APRIL 10, 2024
In the last few days, the Madras and Delhi High Courts have passed a few significant orders on these topics. Let’s take a look at these three orders in this quick tidbit. More than a year later, the Ceritinib controversy has popped up again, this time Natco seeking vacation of the interim injunction.
The IPKat
NOVEMBER 14, 2022
a wise cat that care about environment kindly provided in CC0 Public Domain license by Pixhere.com) Having to make a selection among the many topics covered, this GuestKat finds it interesting to note that during the conference the EPO case G2/21 on 'plausibility', was repeatedly discussed from different angles.
Velocity of Content
FEBRUARY 22, 2023
Given the wide variety of names for chemicals, including structures, unique ids, brand names, generic names, etc., As mentioned above, RightFind Navigate added ChemBL Compounds as a data source, which brings in a new layer of access to bioactive compounds with drug-like properties. Navigate also leverages ChemBL as a vocabulary.
Expert insights. Personalized for you.
105 
Let's personalize your content